New Drug May Slow Cataract Growth and Delay Cataracts From Forming
September 7, 2011
Calpain Therapeutics is working on a new drug to slow cataract growth and even delay cataracts from forming.
The drug targets a protein in eye tissue that, when activated by triggers commonly associated with aging, causes the clouding of the eye lens we know as a cataract. Testing to date of Calpain’s drug compound has shown that it significantly slows cataract progression.
The drug is applied either in the form of drops, or a cream that a patient can put in his or her eyes each night before going to sleep.
Calpain was recently named as one of five finalists in The University of Queensland (UQ) Business Schools $100,000 Enterprize business plan competition.
Click here to learn more about this exciting new drug.
You might also enjoy...
- Ohr Pharmaceutical Launches Clinical Trial to Evaluate Squalamine Eye Drops for Wet AMD
- Do Nanoparticles Called Dendrimers Offer Promise For Treating Macular Degeneration and Retinitis Pigmentosa?
- Ohr Pharmaceutical Announces Positive Preclinical Safety Study Results for Squalamine Eye Drop for Wet-AMD
- New Drug Delivery Device May Treat Retinal Damage Caused by Diabetes
- Bausch + Lomb and Technolas™ Perfect Vision Introduce VICTUS™ Femtosecond Laser Platform
Jump down to form below to submit your own comments